MARKET

TLPH

TLPH

Talphera Inc
NASDAQ
1.320
+0.100
+8.20%
After Hours: 1.340 +0.02 +1.52% 19:10 02/22 EST
OPEN
1.250
PREV CLOSE
1.220
HIGH
1.320
LOW
1.200
VOLUME
110.33K
TURNOVER
0
52 WEEK HIGH
1.610
52 WEEK LOW
0.4250
MARKET CAP
22.38M
P/E (TTM)
-0.4547
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Inspire Veterinary (NASDAQ:IVP) stock increased by 47.8% to $0.2 during Wednesday's pre-market session. Motus GI Hldgs shares rose 47.17% during the day. Talphera stock rose 18.39% and Ocugen increased by 15.38% in the pre- market session. Losers Avinger and Teladoc Health were among the companies that lost ground.
Benzinga · 1d ago
Weekly Report: what happened at TLPH last week (0212-0216)?
Weekly Report · 3d ago
Weekly Report: what happened at TLPH last week (0205-0209)?
Weekly Report · 02/12 12:20
12 Health Care Stocks Moving In Wednesday's After-Market Session
NanoString Technologies (NASDAQ:NSTG) shares moved upwards by 16.5% to $0.06 during Wednesday's after-market session. Tenax Therapeutics and Revelation Biosciences were the biggest gainers. Sana Biotechnology and 23andMe Holding were among the losers.
Benzinga · 02/07 21:31
Talphera files to sell 7.79M shares for its holders
Seeking Alpha · 02/06 21:57
Weekly Report: what happened at TLPH last week (0129-0202)?
Weekly Report · 02/05 12:33
Why Sintx Technologies Shares Are Trading Higher By Over 39%; Here Are 20 Stocks Moving Premarket
Shares of Sintx Technologies, Inc. Rose sharply in today's pre-market trading. The company's shares jumped 39.3% to $0.3393 after the company entered into a research agreement with the U.S. Army on Tuesday. Alphabet shares fell 5% on Tuesday after posting weaker-than-expected earnings results.
Benzinga · 01/31 13:17
Weekly Report: what happened at TLPH last week (0122-0126)?
Weekly Report · 01/29 12:15
More
About TLPH
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.

Webull offers Talphera Inc stock information, including NASDAQ: TLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLPH stock methods without spending real money on the virtual paper trading platform.